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Abstract
Background: Mutations in the Abnormal Spindle Microcephaly related gene (ASPM) are the commonest cause of
autosomal recessive primary microcephaly (MCPH) a disorder characterised by a small brain and associated mental
retardation. ASPM encodes a mitotic spindle pole associated protein. It is suggested that the MCPH phenotype
arises from proliferation defects in neural progenitor cells (NPC).
Results: We show that ASPM is a microtubule minus end-associated protein that is recruited in a microtubule-
dependent manner to the pericentriolar matrix (PCM) at the spindle poles during mitosis. ASPM siRNA reduces
ASPM protein at the spindle poles in cultured U2OS cells and severely perturbs a number of aspects of mitosis,
including the orientation of the mitotic spindle, the main determinant of developmental asymmetrical cell division.
The majority of ASPM depleted mitotic cells fail to complete cytokinesis. In MCPH patient fibroblasts we show that
a pathogenic ASPM splice site mutation results in the expression of a novel variant protein lacking a tripeptide
motif, a minimal alteration that correlates with a dramatic decrease in ASPM spindle pole localisation. Moreover,
expression of dominant-negative ASPM C-terminal fragments cause severe spindle assembly defects and cytokinesis
failure in cultured cells.
Conclusions: These observations indicate that ASPM participates in spindle organisation, spindle positioning and
cytokinesis in all dividing cells and that the extreme C-terminus of the protein is required for ASPM localisation and
function. Our data supports the hypothesis that the MCPH phenotype caused by ASPM mutation is a consequence
of mitotic aberrations during neurogenesis. We propose the effects of ASPM mutation are tolerated in somatic cells
but have profound consequences for the symmetrical division of NPCs, due to the unusual morphology of these
cells. This antagonises the early expansion of the progenitor pool that underpins cortical neurogenesis, causing the
MCPH phenotype.
Background
During neurogenesis the majority of neurons and glia in
the mammalian neocortex arise from the division of
NPC in the neuroepithelial lining of the central cavities
of the brain [1]. Primary NPC have a specific pattern of
mitotic activity. Initially each symmetrical division
increases precursor cell number by generating two pro-
genitor cells per division. Subsequent asymmetric
neurogenic divisions produce one neuron and regener-
ate one progenitor cell [2]. In the developing mamma-
lian cortex the division fate of a cell appears dependent
upon the orientation of the mitotic spindle and hence
the position of the cleavage furrow with respect to the
apical surface of the neuroepithelium [3]. As a result of
the inheritance of cell lineage determinants located at
the apical cell membrane, cleavage parallel to the apical
surface results in neurogenic division where the apical
contents are inherited by one daughter cell and the
basal contents by the other, whereas perpendicular clea-
vage produces two daughter progenitor cells. The
mechanisms regulating spindle orientation and cleavage
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are not well understood.
Autosomal recessive primary microcephaly (MCPH) is
a rare Mendelian disorder characterized by a congenital
deficiency of foetal brain growth, particularly affecting
the neocortex. This results in the formation of a small
but structurally normal brain and associated mental
retardation but no other neurological defects [4,5]. The
concept that MCPH is a primary disorder of neurogenic
mitosis, the result of which is a reduction of cell num-
ber in the developing human brain, is an attractive one.
Mutations that cause the condition have been found
in five genes: microcephalin (MCPH1), which functions
in the DNA damage response pathway; and abnormal
spindle-like microcephaly associated gene (ASPM),
CDK5 regulatory subunit-associated protein 2
(CDK5RAP2), centromeric protein J (CENPJ)a n dS C L /
TAL1-interupting locus (STIL) which are all associated
with aspects of centrosome function [5-13]. The most
common cause of MCPH is mutation of the ASPM gene
[5,14,15] at the MCPH5 locus on chromosome 1q31
[16,17]. All known pathogenic mutations produce a sin-
gle clinical phenotype [5,15] even though they include
nonsense, frameshift, translocation and splice site muta-
tions located throughout the 28 exon ASPM gene
[5,8,15,18-23]. It was originally assumed that mutations
result in either protein truncation or mRNA degradation
via the nonsense mediated decay (NMD) pathway [24].
The human ASPM gene encodes a protein composed of
3477 amino acids [5] that is predicted to contain an
amino terminal microtubule binding domain [25]; two
highly conserved N-terminal short ASNP (ASPM
N-proximal) repeats [8]; two calponin homology
domains; up to 81 calmodulin binding isoleucine-
glutamine (IQ) motifs [5,8,26,27]; an armadillo-like
sequence and a carboxyl terminal region of unknown
function [5,15]. Figure 1A summarizes the domain struc-
ture of the ASPM protein. ASPM is expressed in all pro-
liferating tissues and is upregulated in many cancers [8].
Human ASPM is the orthologue of the Drosophila
abnormal s p i n d l eg e n e( asp) .A s pi si n v o l v e di ns p i n d l e
microtubule organisation in mitosis and meiosis
[25,28-31] and in cytokinesis [32,33]. In dividing Droso-
phila neuroblasts asp mutations cause metaphase arrest,
resulting in reduced CNS development [29]. siRNA
depletion of asp produces a severe loss of microtubule
focus at spindle poles [34]. In mice, elimination of Aspm
results in a reduction in neural stem cell proliferation
and increases the likelihood that NPCs will undergo
asymmetric cell division, implying a reduction in the
total number of progenitor cells formed during brain
development [35]. Inhibition of human ASPM expression
by siRNA-mediated knockdown inhibits tumour cell pro-
liferation [36]. Although it has been hypothesized that
ASPM is required for cell division in the developing
human brain, direct evidence in support of this has been
lacking.
I nt h ep r e s e n ts t u d yw ei n v e s t i g a t et h er o l eo fA S P M
in human cell division and extend the characterization
of the mitotic distribution of human ASPM. We show
that ASPM knockdown in U2OS osteosarcoma cells by
siRNA alters the positioning of the mitotic spindle from
parallel to the substrate to perpendicular to the sub-
strate, effectively alteringt h ed i v i s i o ns y m m e t r yf r o m
symmetrical to asymmetrical. ASPM siRNA-mediated
depletion also induced cytokinesis failure and apoptosis.
Moreover we show that a pathogenic mutation identi-
fied in an MCPH patient, and located in the 3’region of
the ASPM gene instigates the activation of an upstream
in frame cryptic splice donor site, resulting in the spli-
cing out of nine nucleotides (nt) from the ASPM
sequence. The resultant protein exhibits decreased effi-
ciency in localization to spindle poles, suggesting the
presence of the C-terminal domain is of critical impor-
tance for ASPM function. Supporting this, we find that
ASPM C-terminal fragments expressed in transfected
cells induce dominant-negative defects on spindle orga-
nisation and cytokinesis. This study provides further evi-
dence for the function of ASPM in the division cycle of
mammalian cells. We discuss these findings in relation
to cerebral cortex neurogenesis and microcephaly.
Results and Discussion
ASPM is a nuclear protein that relocates to the spindle
pole matrix and central spindle MT minus ends during
mitosis
To determine the intracellular distribution of human
ASPM, rabbit polyclonal antibodies were raised against
ASPM-specific peptide sequences (Figure 1A) and used
to screen a panel of cell lines by immunofluorescence.
Two antibodies against N-terminal peptides (216-1 and
217-2) and one antibody against a C-terminal peptide
(279-3) produced virtually identical staining patterns
(see Additional file 1, 2, 3) in a variety of human cell
types including HeLa, primary human dermal fibroblasts
(HDF), U2OS osteosarcoma cells, SH-SY5Y neuroblas-
toma cells and in COS-7 African green monkey kidney
cells. Pre-incubation with the associated ASPM peptide
negated the ASPM signal (data not shown). As pre-
viously published [37], we found ASPM expression to be
predominantly concentrated in the nucleus during inter-
p h a s e( F i g u r e1 B ) ,h o w e v e rw ed i dn o tf i n de v i d e n c eo f
centrosomal distribution. Consistent with this finding,
the ASPM sequence contains a number of potential
nuclear localization sequences (Figure 1A). No specific
association with microtubules or microtubule-organizing
centres was observed prior to nuclear envelope break-
down. In agreement with previous reports, ASPM
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and onto spindle structures immediately after nuclear
envelope breakdown, and from prometaphase to ana-
phase ASPM was seen almost exclusively associated
with the mitotic spindle (Figure 1C) [8,37,38]. We
localized mitotic ASPM immunoreactivity to pole-proxi-
mal regions of spindle microtubules, where it formed a
ring around the spindle poles. This ring enclosed but
did not extensively overlap with g-tubulin immunoreac-
tivity (Figure 1D), though it co-localised with Dynactin
Figure 1 Organisation of the ASPM protein and its cellular distribution during mitosis. A. Structure of the 3477 amino acid human ASPM
protein. The region corresponding to the microtubule-binding domain of Drosophila Asp [24] is shown in white. The calponin homology
domains (aa920-1261) are in light grey; ASNP repeats are dark grey boxes (aa316-342, 366-400); 81 IQ domains (aa1267-3225) are shown as
vertical stripes; the armadillo repeat-like domain (aa3294-3327) is a black box; and the C-terminal region is depicted by diagonal stripes. The
location of potential nuclear localization sequences are indicated by asterisks and the location of the peptides used to raise polyclonal
antibodies, by dashed arrows. B-F. Analysis of ASPM distribution following immunostaining. HeLa cells were fixed and stained with antibodies
specific for ASPM (green), anti-a-tubulin (red) and with DAPI (blue) to identify nuclei. Panels B-E utilised Anti-ASPM 216-1, whilst anti-ASPM 279-3
was used in panel F. B. ASPM is predominantly nuclear in interphase cells. Scale bar = 10 μm. C. ASPM is localised to the spindle poles during
metaphase. Scale bar = 5 μm. D. A globular distribution of ASPM (green) is seen around the g-tubulin (red) immunopositive core of metaphase
HeLa cell spindle poles. DNA (DAPI staining) is shown in blue (confocal image). Scale bar = 2.5 μm. E. Single 0.5 μm confocal section through
the centre of a telophase HeLa cell immunostained to reveal ASPM (green) and a-tubulin (red). In addition to broad spindle pole-associated
labelling (arrowhead), ASPM also localizes to the minus ends of central spindle microtubules (arrow). Scale bar = 2.5 μm. F. A late telophase
fibroblast immunostained with anti-ASPM 279-3 (green), anti-a-tubulin (red) and with DAPI (blue). ASPM is predominantly localized at the
midzone of the central spindle. Scale bar = 10 μm. G. Immunoblotting of cell lysates of COS7 cells (lane 1), U2OS cells (lane 2), primary
fibroblasts (lane 3) and HeLa cells (lane 4) with anti-ASPM 217-2 antibody. This identifies a protein of approximately 410 kDa in each lane. A blot
stained with anti-b-actin is shown as loading control.
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matrix (PCM, data not shown). In anaphase cells the
mitotic spindle has flattened and ASPM maintains its
spindle pole localisation, was observed along the micro-
tubules leading to the pole and a fraction of ASPM was
found at the minus ends of central spindle microtubules
(Figure 1E). Throughout telophase and cytokinesis
ASPM was predominantly positioned in a narrow ring
at the centre of the midbody (Figure 1F and see Addi-
tional file 4). This localisation was most visible when
using the C-terminal antibody 279-3.
Immunoblot analysis using the 217-2 N-terminal anti-
ASPM antibody identified a 410 kDa ASPM band in
each of a panel of human and monkey cell lines (Figure
1G). This band corresponds to the expected size of the
3447 amino acid wild-type ASPM protein. Other investi-
gators have reported that at least three predominant
ASPM splice variants may exist [8]. In accordance with
the reported literature, 217-2 would be predicted to
recognise wildtype ASPM and the largest variant V1,
however we saw no evidence for the existence of V1 in
o u rw h o l ec e l le x t r a c t s .W ew e r eu n a b l et oo p t i m i s e
antibodies 216-1 and 279-3 for Western blotting at
endogenous levels of ASPM. However, these antibodies
recognise recombinant forms of the ASPM protein
expressed in and purified from bacteria (results not
shown).
ASPM distribution is microtubule dependent
To examine the dependence of ASPM localization upon
microtubules, we first treated HeLa cells with 5 μg/ml
of the microtubule depolymerising drug nocodazole for
60 minutes. Under these conditions g-tubulin immunos-
taining was maintained at spindle poles but ASPM 216-
1 staining was lost, indicating that the mitotic distribu-
tion of ASPM is microtubule-dependent (Figure 2A).
We next challenged HeLa cells with 10 μM taxol for 60
minutes, a treatment that induces the formation of mul-
tiple microtubule asters in mitotic cells. ASPM 216-1
immunostaining was observed at the centre of these
asters (Figure 2B), suggesting a specific localization to
microtubule minus ends. ASPM was not specifically
associated with the anastral g-tubulin foci also seen in
taxol-treated cells (Figure 2C).
SiRNA mediated ASPM knockdown leads to repositioning
of the mitotic spindle and cytokinesis dysfunction
To determine the effects of loss of ASPM function upon
cell cycle progression we carried out ASPM RNA inter-
ference experiments. As a normal human NPC culture
amenable to RNAi studies was not available we chose to
perform these tests in the extensively characterised and
readily transfectable U2OS osteosarcoma cell line using
two individual ASPM siRNAs (ASP1 and ASP2) and a
luciferase (GL3) control. A clear reduction in ASPM at
the spindle poles of dividing cells was detected after
transfection with ASP1 and ASP2 for 72 or 96 hours. By
72 hours post transfection with ASP1, ASPM (detected
with the anti-ASPM 216-1 antibody at the spindle poles
of mitotic cells was detectable in only 24% (6/25) of
metaphase cells and completely knocked down in 76%
of dividing cells, whereas ASP2 siRNA achieved a partial
knockdown in 92% (23/25) metaphase cells (Figure 3A)
and complete knock down in 8% of dividing cells. Com-
parative immunofluorescence analysis of average integral
intensity measurements of immunofluorescently labelled
centrosomal ASPM was performed for twenty-five meta-
phase U2OS cells treated with either ASP1, ASP2 or
GL3 siRNAs. In comparison to the average ASPM spin-
dle pole signal measured in the GL3 treated metaphases,
a significant decrease of 84.3% in the average integral
intensity of ASPM signal at the spindle pole was calcu-
lated after 72 hr treatment with ASP1, and 55.2% after
treatment with ASP2 (Table 1). Immunofluorescence
and Western blotting could not detect a change in over-
all expression level of ASPM in interphase cells (Figure
3B,C), suggesting that ASPM is stabilised when asso-
ciated with the nuclear matrix and is more open to
degradation after nuclear envelope breakdown. We
therefore chose to investigate the phenotype associated
with knock down of ASPM at the spindle poles of divid-
ing cells.
A substantial reduction in proliferation of U2OS cells
was observed after siRNA treatment in a Celltitre Blue
cell viability assay (Figure 3D). Assessment of the pro-
portions of 2N:4N DNA content by flow cytometry 48
hours and 72 hours after ASPM siRNA treatment distin-
guished 4N cells in G2/M from tetraploid cells that had
failed cytokinesis by confirming the presence or absence
of Cyclin B1. We identified an increase in the propor-
tion of 2N cells in G1, a reduction of cells in G2/M and
an increase in tetraploid cells in ASPM siRNA treated
cells (Figure 3E). These data are consistent with both a
decrease in the number of cells undergoing mitosis and
a failure of cytokinesis. This observation was corrobo-
rated by microscopic examination of immunofluores-
cently labelled cells after 48 and 72 hours of ASP1 and
ASP2 siRNA knockdown, which indicated a decrease in
mitotic index and an increase in multinucleate cells and
large mononucleate cells with multiple centrosomes
consistent with a failure to complete cytokinesis
(Figure 3F). The number of cells in cytokinesis, defined
in this instance as daughter cells linked by narrow cyto-
plasmic bridges containing midbodies, was also
decreased by ASPM siRNA.
To gain further insight into the ASPM knockdown
phenotype, we carried out phase contrast time-lapse
imaging of living U2OS cells 72 hours post-ASP1 or
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experiments were combined to produce the final data
set. We monitored 126 cell divisions of GL3 treated
U2OS cells and 94 cell divisions following ASP1 siRNA.
Depletion of ASPM had a profound effect on U2OS cell
division. Three major phenotypic anomalies were identi-
fied; an increase in the proportion of divisions with the
mitotic spindle perpendicular to the plate surface, an
increase in cytokinesis failure, and an increase in
apoptosis.
Normal symmetrical division necessitates positioning
of the mitotic spindle parallel to the surface of the ima-
ging dish resulting in cleavage plane orientation perpen-
dicular to the dish (Figure 4A, see Additional file 5). In
37% of ASP1 siRNA knockdowns (n = 36) random
deviation in the position of the mitotic spindle was
observed (Table 2) with a significant increase in spindle
positioning approximately perpendicular to the surface
of the dish (Figure 4A, see Additional file 6). This spin-
dle alignment is reminiscent of that observed in asym-
metric divisions in mouse progenitor cells of the
neuroepithelium [35]. We therefore termed these divi-
sions asymmetric. In comparison, only 10.3% (n = 13) of
GL3 treated cells exhibited such asymmetric divisions.
A second consequence of ASPM depletion observed by
time-lapse imaging was cytokinesis failure (Table 2), lead-
ing to the formation of multinucleated cells. Although we
observed this phenomenon in a minor population of ASP1
siRNA-treated cells that underwent symmetrical division
(6.4%, n = 6), the phenotype was far more prevalent in
ASP1 treated cells that had undergone asymmetric divi-
sions (28.7%, n = 27) (Figure 4A, see Additional file 6). In
contrast, cytokinesis failure was observed in only 3.2% (n =
4) of symmetric cell divisions and 4% (n = 5) of asymmetric
Figure 2 The ASPM spindle association is microtubule-dependent. A. Panel showing a nocodazole-treated mitotic HeLa cell immunostained
for ASPM 216-1 (green), g-tubulin (red) and DAPI (blue). ASPM is not clustered around the g-tubulin of the spindle poles in the absence of
microtubules. Scale bar = 5 μm. B. Panel showing a taxol-treated mitotic HeLa cell immunostained for ASPM 216-1 (green), a-tubulin (red) and
DAPI (blue). ASPM concentrates in the centre of taxol-induced microtubule asters (arrows). Scale bar = 5 μm. C. Panel showing a taxol-treated
mitotic HeLa cell immunostained for ASPM 216-1 (green), g-tubulin (red) and DAPI (blue). ASPM (arrowhead) does not specifically co-localize with
g-tubulin foci (arrow) in taxol-treated cells. Scale bar = 5 μm.
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asymmetric cell division initially results in one daughter
cell anchored to the culture dish with the second daughter
cell positioned above the first (i.e., being extruded towards
the observer see Additional file 6) and not attached to the
substrate. We observed that in many instances the second
daughter cell was able to subsequently make contact with
the dish and successful cytokinesis occurred. Only 38% (5
of 13 cells) of asymmetrical divisions in GL3 control
experiments failed cytokinesis compared with 75% (27 of
36 cells) of asymmetrical ASP1 treated cells. Therefore
asymmetrical division per se does not fully account for
increased cytokinesis failure in ASP1 siRNA treated U2OS
cells.
Figure 3 Phenotypic traits of siRNA mediated depletion of ASPM in U2OS cells. A. Reduction in spindle pole associated ASPM (using the
anti-ASPM 216-1 antibody), 72 hrs post transfection with ASP1 and ASP2 siRNAs relative to GL3 control dsRNA Scale bar = 10 μm. B. ASPM
(216-1 antibody) expression in interphase cells 72 hrs post GL3, ASP1 and ASP2 transfection. Scale Bar = 10 μm. C. Western Blot using rabbit
polyclonal anti-ASPM 217-2 antibody, showing ASPM expression in lysates from GL3, ASP1 and ASP2 treated U2OS cells. A b-actin loading
control is shown. 25 μg protein for each sample was loaded. D. Celltitre Blue cell viability assay was carried out 72 hours post siRNA treatment,
showing a reduction in cell viability in ASP1 and ASP2 siRNA transfected cell cultures. E. Flow cytometric analysis of DNA content and cyclin B1
status 48 and 72 hours post ASPM siRNA treatment, demonstrating a decrease in the number of cells in G2/M and an increase in the number of
tetraploid G1 cells. F. Analysis of immunofluorescently labelled cells treated for 48 and 72 h with ASP1 and ASP2 siRNAs. A decrease in mitotic
index and an increase in the number of multinucleate cells and cells with centrosome numbers greater than 2 are seen following ASPM
knockdown. A decrease in the number of cells displaying morphological hallmarks of cytokinesis, such as the presence of a midbody, is also
seen. These observations are consistent with a failure to complete cytokinesis.
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in cells transfected with ASP1, 72 hours post transfec-
tion. Apoptosis was observed in mononucleate cells,
binucleate cells (Figure 4A, see Additional file 7) and in
cells exiting mitosis but exhibiting cytokinesis failure.
To quantitate the extent of ASP1 siRNA induced apop-
tosis we performed an in situ activated caspase-3 assay
on unfixed U2OS cells after 96 hours of siRNA treat-
ment (Figure 4B). On average, ASP1 siRNA treated cells
demonstrated a 2.7 fold increase in caspase-3 positive
apoptotic cells compared to control GL3 siRNA cells
(mean percentage of apoptotic GL3 siRNA cells in a
total cell population = 7% (s.d. = 3.3%) compared to
mean percentage of apoptotic ASP1 siRNA cells =
18.7% (s.d. = 6%) (Figure 4C).
It has previously been reported that ASPM is required
for precise orientation of the mitotic spindle in specia-
lised mouse NPC [35]. Our data demonstrates that
ASPM function is a determinant of spindle position and
division symmetry even in non-neuronal derived cells,
suggesting that complete absence of ASPM function
during human development might be expected to affect
whole body development. Since this is not the observed
phenotype in MCPH, the effect of ASPM mutation on
the function of the ASPM protein expressed in MCPH
patients was a logical progression of our studies.
An ASPM C-terminal splice donor site mutation induces
novel splicing and reduces mitotic spindle pole
association
ASPM contains a number of potential functional
domains. Following the positional cloning of the ASPM
gene, the initial genotype-phenotype correlation studies
in MCPH patients did not reveal a clustered distribution
of microcephaly-associated mutations in ASPM [5,15]
and there were therefore few clues to which of these
domains were most important for ASPM function.
We have previously characterized a C-terminal ASPM
mutation as a homozygous intronic mutation at IVS25
+1G > T (9984 +1 G > T), identified in individuals of a
consanguineous family of Northern Pakistani origin [15].
This mutation lies downstream of the Armadillo repeat-
like domain (Figure 5A). Splice site prediction programs
forecast the outcome of this mutation to be the removal
of the intron 25 splice donor site, resulting in transla-
t i o n a le x t e n s i o no fe x o n2 5b y2 9a m i n oa c i d sb e f o r e
the incorporation of a stop signal. We predicted this
would result in either the synthesis of a truncated
ASPM protein of 395 kDa (3357 amino acids) that
would not include the anti-ASPM 279-3 peptide
sequence, or that it could lead to ASPM depletion due
to mRNA degradation via the NMD pathway.
To determine the effect of the IVS25+1G > T muta-
tion on ASPM mitotic expression and localisation, com-
parative immunofluorescence microscopy of dividing
ASPM
wt and ASPM
IVS25 +1G > T fibroblasts was per-
formed using our N-terminal 216-1 anti-ASPM anti-
body. Quantitative analysis of spindle pole staining
revealed a significant reduction in ASPM levels at the
PCM in ASPM
I V S 2 5+ 1 G>Tfibroblasts (Figure 5B, C)
(n = 80, average integral intensity ASPM
wt = 16427.01
μm
2 (s.e.m. = 1166.3 μm
2), average integral intensity
ASPM
IVS25 +1G > T = 2325.1 μm
2 (s.e.m. = 260.1 μm
2),
p = < 0.0001; Average area ASPM
wt=4 . 8 0μm
2(s.e.m. =
0.27 μm
2), average area ASPM
IVS25 +1G > T t=1 . 2 8μm
2
(s.e.m = 0.08 μm
2), p = < 0.0001). Unexpectedly, analysis
of ASPM
IVS25 +1G > T fibroblasts immunofluorescently
labelled with the C-terminal anti-ASPM 279-3 antibody
also revealed weak but clearly visible spindle pole stain-
ing (Figure 5B), suggesting the IVS25+1G > T mutation
did not induce a protein truncation.
To investigate the effect of the IVS25+1 G > T ASPM
mutation on the ASPM protein, we carried out immuno-
blotting of cell lysates from control (ASPM
wt) and patient
(ASPM
IVS25 +1G > T) fibroblasts with the 217-2 N-terminal
anti-ASPM antibody. Expression of full length ASPM (410
kDa) in ASPM
wt cell lines was observed and a band of
approximately similar size and equivalent intensity was
detected in ASPM
IVS25 +1G > T protein extracts (Figure
5D). Thus the IVS25 +1 G > T mutation does not instigate
NMD or protein instability in fibroblasts. Due to the large
size of both the full length ASPM and the predicted IVS25
+1G > T truncated product (395 kDa) we were unable to
directly determine size differences in the proteins by
immunoblotting.
To further explore the effect of the IVS+1G > T
mutation, RT-PCR of ASPM exons 24-28 of ASPM
wt
and ASPM
IVS25 +1G > T fibroblast mRNA was performed
and the single PCR product obtained from each was
sequenced. Wildtype ASPM sequence was observed in
the ASPM
wt fibroblast mRNA. As expected the G > T
mutation at the exon 25 splice donor site invalidated
the native splice site sequence in the ASPM
IVS25 +1G > T
mRNA. However, transcription did not continue for the
Table 1 Down regulation of ASPM in response to siRNA
mediated ASPM depletion in metaphase U2OS cells.
GL3 ASP1 ASP2
Average integral intensity (μm
2) 14805 2318 6631
Knockdown of spindle pole expression (%) 0 84.3 55.2
p value <0.001 0.005
Comparative immunofluorescence analysis, measured as average integral
intensity, was performed on the immunofluorescent centrosomal ASPM signal
of twenty-five metaphase U2OS cells treated with ASP1, ASP2 or GL3 siRNAs.
In comparison to the average integral intensity of ASPM spindle pole signal
measured in the GL3 treated metaphases, a significant decrease in the
average integral intensity of ASPM signal at the spindle pole was calculated
after 72 hr treatment with ASP1, and with ASP2. The knock down is expressed
as a percentage of the expression in GL3 cells. In each case t-tests showed
the levels of knockdown to be significant.
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Page 7 of 17Figure 4 siRNA mediated ASPM induces misorientation of the plane of cell division, cytokinesis failure and increased apoptosis in
U2OS cells. A. Panels showing phase contrast images of living U2OS cells taken from time-lapse movies. Time points are shown in the bottom
left hand corner of each image. Top row. Normal symmetrical division of a GL3 siRNA treated control cell with the cleavage plane oriented
perpendicular to the cell substrate (see Additional file 5). Scale bar = 10 μm. Middle row. ASP1 siRNA treated cell undergoing an asymmetric
division with the mitotic spindle positioned perpendicular to the cell substrate. This division led to cytokinesis failure with the formation of a
binucleate cell. Arrowhead shows the upper daughter cell moving out of the focal plane towards the observer as the cleavage furrow is formed
parallel to the surface of the imaging dish. An arrow indicates the lower daughter cell still attached to the surface of the dish (see Additional file
6). Scale bar = 10 μm. Bottom row. Binucleated ASP1 siRNA treated cell undergoing apoptosis (see Additional file 7). Scale bar = 10 μm. B. Flow
cytometric analysis of caspase-3 assayed 96 hours after ASP1 and GL3 siRNA treatment. An increase in the population of apoptotic (dead) cells is
observed in ASP1 siRNA experiments. C. Histogram showing the mean percentage of apoptotic cells in ASP1 and GL3 siRNA caspase-3 assays. A
2.7 fold increase in the percentage of apoptotic cells in the ASP1 siRNA population was identified compared to the GL3 siRNA population.
Standard deviation values for the mean are shown as vertical bars.
Table 2 Effect of siRNA mediated ASPM depletion on spindle pole position and cytokinesis.
Total number of
divisions
Symmetric division with
cytokinesis
(% of total)
Symmetric division with
cytokinesis failure
(% of total)
Asymmetric division
with cytokinesis
(% of total)
Asymmetric division with
cytokinesis failure
(% of total)
GL3 126 109 (86.5%) 4 (3.2%) 8 (6.3%) 5 (4.0%)
ASP1 94 52 (55.3%) 6 (6.4%) 9 (9.6%) 27 (28.7%)
Time-lapse imaging of living U2OS cells was performed 72 hours post-GL3 and ASP1 siRNA treatment. The results of four independent experiments were
combined to produce the final data set. Depletion of ASPM had a profound effect on U2OS cell division, resulting in an increase in the proportion of divisions
with the spindle positioned perpendicular to the plate surface (asymmetrical division) and an increase in cytokinesis failure.
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IVS25+1G > T mutation produces a novel splice variant with decreased efficiency for spindle pole localisation. A. Schematic
of the ASPM protein showing the location of the ASPM
IVS25+1G > T splice site mutation (filled arrows with an upper diamond). Domains of the
protein are indicated as described in the legend to Figure 1. Location of epitopes of anti-ASPM antibodies are shown beneath the protein. B.
Fibroblasts at metaphase immunostained using 216-1 anti-ASPM antibody (N-terminal) and the 279-3 anti-ASPM antibody, raised against a C-
terminal peptide sequence. Note the reduced ASPM localization at the mitotic spindle poles of ASPM
IVS25+1G > T cells. Scale bar = 10 μm. C.
Chart representing integral intensity of ASPM 216-1 antibody staining at the spindle poles of ASPM
wt and ASPM
IVS25+1G > T fibroblast cells.
Horizontal lines indicate the average integral intensity of the immunostaining. Standard error bars are present. ASPM
IVS25+1G > T was at
statistically significantly lower level (asterisks) at the spindle poles than ASPM
wt when compared using a paired two tailed t-test. P = < 0000.1. D.
Immunoblotting of fibroblast control (WT) and ASPM
IVS25+1G > T (Patient) lysates with 217-2 anti-ASPM antibody and anti b-actin. Equivalent levels
of stable ASPM protein are expressed by each cell culture, indicating the IVS25+1G > T mutation does not induce nonsense mediated decay. E.
Sequence analysis of exon 25-exon 26 control ASPM
wt and Patient ASPM
IVS25+1G > T cDNA. The point of removal of the nine nucleotides due to
the IVS25+1G > T mutation is indicated by an asterisk. F. IVS25+1G > T mutation removes the exon 25 splice donor site and instigates the
utilisation of an in frame splice donor site nine nucleotides downstream. The resultant ASPM
IVS25+1G > T protein is lacking just three amino acids
(3326-3328).
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STOP codon. Unexpectedly, an in-frame cryptic splice
donor site nine base pairs upstream was recognised and
utilised (Figure 5E, F). The use of the upstream cryptic
splice donor site would result in the production of an
ASPM protein from which only a tripeptide motif
(amino acids 3326-3328) is deleted (Figure 5E). Our
immunofluorescence data therefore indicates that the
loss of three amino acids in the C-terminus of ASPM is
apparently sufficient to drastically reduce the ability of
the protein to localise with the microtubules at the
PCM at the spindle poles. The fact that fibroblasts from
this MCPH patient have a significant decrease in the
quantity of microtubule associated ASPM suggests the
presence of a functional C-terminal domain in ASPM
that is critical for normal ASPM function.
Expression of C-terminal fragments of ASPM inhibits
spindle assembly and induces mitotic delay in HeLa cells
Our immunostaining data in patient cells indicates a
function mediated by the extreme C-terminal region of
ASPM is required for its localization to spindle poles.
We therefore examined the consequences for mitotic
cells of expressing C-terminal fragments of ASPM upon
mitotic progression. Plasmids directing the expression of
GFP fused to three different fragments of 301 (D1), 222
(D2) and 163 (D3) amino-acids from the C-terminal
sequence of ASPM were created (Figure 6A) to deter-
mine whether ectopic expression of these fragments
would disrupt the function of endogenous ASPM in a
dominant-negative manner.
HeLa cells were transfected with the plasmids and
observed 24 hours post transfection. Each construct led
to similar abnormalities that included the generation of
a large number of cells with morphological features con-
sistent with an early mitotic arrest (Figure 6B, panels a-
c) and in many cells membrane blebbing was also evi-
dent (Figure 6B, panels b-c). The DNA within these
cells was highly condensed and occasionally fragmented,
while spindle microtubule organisation was severely dis-
rupted. Where visible, microtubule focusing and spindle
formation appeared to be fundamentally impaired (Fig-
ure 6B, panel a, arrowheads). In most cells the density
of microtubules was decreased (Figure 6B, panel b,
arrowheads). g-tubulin immunostaining invariably
revealed the presence of two separate foci in these cells
(Figure 6B, panel c, arrows), consistent with the hypoth-
esis that these were cells displaying a disrupted mitosis.
Endogenous ASPM immunoreactivity was dispersed (not
shown). This is consistent with the observation of
diminished microtubule density and our earlier finding
that the ASPM spindle pole association is microtubule-
dependent. It is also consistent with the interpretation
that expression of these ASPM fragments directly
inhibited the localisation of endogenous ASPM to spin-
dle poles. Of control cells expressing GFP alone, 3% (n
= 245) displayed an apoptotic or mitotic delay pheno-
type, in comparison with 33% (n = 135) of cells expres-
sing ASPM-D1-GFP; 26% (n = 127) of cells expressing
ASPM-D2-GFP; and 17% (n = 131) of cells expressing
ASPM-D3-GFP. Similar observations were obtained in
transfected COS-7 cells (not shown). We conclude that
a high proportion of HeLa cells expressing ASPM
C-terminal fragments, particularly those containing the
whole of the armadillo repeat-like region (D1 and D2),
are defective in assembling a functional spindle. This
leads to mitotic arrest and eventual apoptosis.
Expression of ASPM COOH-terminal GFP-fusion proteins
induces cytokinesis failure in COS-7 and HeLa cells
In addition to the severe mitotic defects seen in COS-7
and HeLa cells transfected with C-terminal fragments of
ASPM, we also observed a subset of cells that appeared
to have undergone mitosis but had failed to complete
cytokinesis (Figure 6B, panels d-f). Defects ranged from
cells containing large, highly lobular nuclei and periph-
eral microtubule bundles (Figure 6B, panel d, arrows) to
cells containing discrete nuclei separated by aberrant
microtubule arrays (Figure 6B, panel e, arrow), or struc-
tures resembling residual central spindles (Figure 6B,
panel f, arrow). In neither case was there clear evidence
for the presence of a cleavage furrow.
To exclude fixation artefacts we used co-expression of
a GFP-tagged microtubule plus-end binding protein, EB3
[39,40] as a means of observing centrosomes and the tips
of growing microtubules and midbody structures in living
COS-7 cells. Expression of low levels of EB3-GFP alone
had no significant impact on cell division in transfected
COS-7 cells (J. M. Askham, unpublished data, 41). The
phenotypes of COS-7 cells co-expressing ASPM-D2-GFP
and EB3-GFP confirmed our immunostaining observa-
tions (Figure 6C). Expression of ASPM-D2-GFP alone led
to the formation of binucleated cells (Figure 6C panel a).
Co-expression of EB3-GFP revealed that these cells con-
tained central spindle structures or loose parallel micro-
tubule arrays (Figure 6C, panel b-d). In some examples
centrosomes were seen in close association with well-
separated nuclei (Figure 6C, panel d), indicating that the
primary defect in these cells was a failure in cytokinesis
after the completion of chromosomal segregation. The
observations from both fixed and living COS-7 cells were
therefore consistent with a role for ASPM in organizing
the central spindle microtubule array in mitotic cells
from anaphase onwards.
Conclusions
Our study provides a mechanism by which mutations in
the human ASPM gene could result in a developmental
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the MCPH phenotype arises due to defective NPC divi-
sion. By examining the consequences of siRNA mediated
knockdown of spindle pole associated ASPM expression
and the phenotypes seen following expression of fusion
proteins derived from the ASPM C-terminus we have
identified critical roles for human ASPM in spindle
microtubule organisation, spindle positioning and in the
regulation of cytokinesis even in a non-neural cell type.
Similar phenotypes have been previously reported in
Drosophila asp mutants [25,28-33]. We suggest that
ASPM is a reasonably stable protein and that nuclear
matrix associated ASPM is less open to degradation
than ASPM after nuclear envelope breakdown. ASPM
was recently confirmed as a gene involved in the regula-
tion of mitosis in human cells as part of the substantive
MitoCheck integrated research project ([42]http://www.
mitocheck.org). As an element of this high-throughput
whole genome RNAi screen, automated live cell image
analysis of ASPM knockdown identified similar pheno-
types to those identified in our study. Although mitotic
spindle position was not a phenotype for which analyti-
cal parameters were specifically established, other mito-
tic phenotypes that could lead to a decrease in cell
Figure 6 Mitotic defects in transfected HeLa and COS-7 cells expressing C-terminal ASPM GFP fusion proteins. A. Organisation of the
3477 amino acid human ASPM protein as described in the legend to Figure 1. C-terminal fragments expressed as fusion proteins with GFP are
indicated D1-D3. Position of the C-terminal mutation (IVS25+1G > T) is indicated by an arrow. B. Panels a, b; HeLa cells expressing ASPM-D1-GFP
immunostained to reveal GFP (green), a-tubulin (red) and DAPI (blue) then examined by confocal microscopy. Aggregates of fusion protein are
indicated by arrows. Microtubules are disorganized and unfocused (arrowheads) and spindle poles cannot be identified. Scale bars = 5 μm. Panel
c; HeLa cells expressing ASPM-D1-GFP immunostained to reveal GFP (green), g-tubulin (red) and DAPI (blue). These abnormal cells possessed two
spindle poles (arrows) and condensed DNA, suggesting mitotic arrest. Scale bar = 10 μm. Panels d-f; COS-7 cells expressing ASPM-D1-GFP
immunostained to reveal GFP (green), a-tubulin (red) and DAPI (blue). Transfected cells were large and binucleate (panels e-f) or possessed
abnormal lobular nuclei (panel d). Peripheral microtubule arrays or bundles were present (panels d-e, arrows). Panel f shows a binucleate cell
containing a midbody (arrow). Scale bar = 20 μm. C. Aberrant cytokinesis in living COS-7 cells expressing ASPM-D2-GFP. Panel a; a binucleate
COS-7 cell expressing ASPM-D2-GFP. Small aggregates of fusion protein can be seen. Panels b-d; COS-7 cells co-expressing ASPM-D2-GFP and
EB3-GFP, used as a marker of microtubule organisation. Binucleate cells containing EB3-GFP positive midbodies (panels b and c, white arrows) or
no midbody and a loose microtubule array (panel d, black arrow) are shown. Black arrow in panel c indicates the position of an incomplete and
unusually asymmetrical cleavage furrow. White arrows in panel d indicate the position of centrosomes associated with the two nuclei,
suggesting chromosomal segregation has occurred but cytokinesis has failed. In all panels asterisks indicate the location of nuclear structures.
Images are shown in inverted grayscale for clarity. Scale bar = 10 μm.
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observed with further phenotypes of mitotic delay, pro-
blems with metaphase alignment, cell death and poly-
lobed nuclei identified with one of two siRNAs utilised.
We have previously shown that Aspm is preferentially
expressed during cerebral cortical neurogenesis in the
m o u s eb r a i n[ 5 ] .T h et i m eo fm a x i m a lAspm expression
in the neuroepithelium corresponds to the period of
proliferative cell division, and the subsequent down-reg-
ulation of Aspm expression is concomitant with a switch
to asymmetrical cell division [35]. We have now demon-
strated that inhibition of ASPM function by siRNA
causes a highly penetrant loss of precision in the place-
ment of the mitotic spindle in dividing U2OS cells,
resulting in an alteration of division mode from the
symmetrical to the asymmetrical plane. This implies
that in U2OS cells symmetrical cell division in a plane
that is perpendicular to the substrate is an active pro-
cess that requires functional ASPM, rather than a simple
default pathway. Our data therefore demonstrates that
the requirement for ASPM in the maintenance of sym-
metrical divisions is not limited to specialised NPCs as
previously assumed, but that it plays a general role in
mitotic cells.
A logical consequence of this hypothesis is that the
normal development of the whole human body should
be affected by ASPM loss of function. Indeed in Droso-
phila loss of asp function results in larval lethality
[25,28-33]. Paradoxically however, the only known phe-
notype in individuals with homozygous mutations in
ASPM is MCPH [5,15]. Mutations in ASPM are scat-
tered throughout the gene, yet they result in a single
clinical MCPH phenotype. Our immunoblot data of
ASPM expression in fibroblast lysates from an MCPH
patient carrying the IVS25+1G > T homozygous muta-
tion established that the MCPH phenotype in this
patient did not result from complete ASPM loss and
confirmed a previous report that ASPM mutation does
not instigate the NMD pathway [8]. Partly functional
ASPM proteins may therefore be expressed in the cells
of MCPH individuals, and we hypothesised that ASPM
mutations caused protein truncations and that the
MCPH phenotype resulted from the common loss of a
C-terminal functional domain that led to partial loss of
ASPM function. Surprisingly, our data from patient cells
demonstrates that the MCPH phenotype can arise from
a cryptic splicing event that r e m o v e so n l yn i n en u c l e o -
tides of intragenic sequence within the C-terminal
region of ASPM and results in a reduction in ASPM
localisation to the spindle poles. The minimal IVS25
+1G > T mutation therefore causes a decrease in the
efficiency of ASPM spindle pole localisation without an
associated decrease in overall ASPM protein levels or a
major increase in gross mitotic abnormalities in patient
fibroblasts. We propose that expression of this subtly
impaired mutant ASPM protein is sufficient to induce
small deviations in the precision of mitotic spindle posi-
tioning in symmetrically dividing cells. This contrasts
with the severe mitotic phenotypes seen in cultured
cells following more profound disruption of ASPM func-
tion by siRNA knockdown of ASPM spindle pole
expression, or expression of dominant negative ASPM
C-terminal domains.
The existence of individuals homozygous for muta-
tions in ASPM who exhibit a small brain but who are
otherwise grossly normal leads us to infer that either (a)
a functional compensatory mechanism exists in somatic
cells or (b) neurogenic cell divisions are sufficiently dif-
ferent to the majority of somatic cell divisions to be pro-
foundly and differentially affected by a subtle
perturbation of ASPM function. The reason for this may
lie in the unique morphology of the cells undergoing
division in the neuroepithelium during cortical expan-
sion [35]. In vertebrates, apical NPC are apicobasally
elongated to a remarkable extent and possess a small
apical surface. To execute accurate symmetrical divi-
sions in such cells would require extremely precise clea-
vage along the apicobasal axis [43]. Small deviations in
spindle position leading to cleavage plane reorientation
would result in a transition from symmetrical to asym-
metrical division. In the majority of somatic cells such
deviations could be tolerated due to their relatively large
apical and basal surfaces. However in NPC such devia-
tion may be sufficient to drive a decrease in the number
of cells successfully completing symmetrical cell divi-
sion. This would impair the expansion of the progenitor
pool that normally occurs at early stages of cortical
development. As a consequence, the NPC pool would
be insufficient to produce the number of neurones
required for a normal sized brain.
What then is the function of ASPM during the later
stages of mitosis? We observed an ASPM localisation at
the minus ends of central spindle microtubules during
anaphase and at the centre of the midbody during telo-
phase and cytokinesis. Microtubules of the mitotic appa-
ratus are a critical contributor to cleavage furrow
positioning. Both astral microtubules and overlapping
equatorial MTs in the central spindle have been impli-
cated as playing a significant role in this process
[44-47]. We therefore see a number of possibilities for
ASPM function during cytokinesis. ASPM might directly
contribute to the organisation of midzone microtubules
with the cytokinesis defects seen after ASPM functional
inhibition arising secondary to central spindle disorgani-
sation. Alternatively, its presence at the centrosome
might influence the function of astral microtubules. It
also seems possible that ASPM might participate more
directly in the coupling of spindle microtubule function
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m i g h tb ea b l et oi n f l u e n c et h e local activity of myosins
through its interactions with EF-hand Ca2+ binding fac-
tors such as calmodulin, or to influence signalling events
during cytokinesis through interactions with binding
partners such as citron kinase [38].
In conclusion, a major finding of our study is that
ASPM plays a role in cell division, not just those in
NPCs, but in other cell types. We propose that MCPH5
patients have enough residual ASPM activity to success-
fully complete functionally symmetrical cell divisions in
all tissues except the developing brain, where extremely
unusual morphological constraints result in a specific
defect in cortical neurogenic mitosis in response to
imprecise spindle position. In this we echo the argu-
ments presented by Fish et al., in an authoritative com-
mentary on NPC division [43]. We have also identified a
three amino acid sequence in the C-terminal domain of
ASPM in an MCPH patient reduces localisation of
ASPM to the PCM implying that this region of ASPM
mediates an important function in NPCs. Future studies
w i l lb ea i m e da td e f i n i n gw hether this region of ASPM
mediates an important interaction with a novel binding
partner.
Methods
Cell culture
HeLa and COS-7 cells were obtained from the European
Collection of Cell Cultures. U2OS human osteosarcoma
cells and SH-SY5Y neuroblastoma cells were obtained
from the ATCC Cell Biology Collection (ATCC-LGC
P r o m o c h e mP a r t n e r s h i p ,S o u t hL o n d o n ,U K ) .H u m a n
neonatal dermal fibroblasts (ASPM
wt) were obtained
from Genlantis (San Diego, California). Each cell line
was maintained in accordance to manufacturer’s
guidelines.
The MCPH5 patient fibroblast cell culture (ASPM
IVS25
+1G > T) was created from a forearm skin biopsy. The
collection of biopsy sample was approved by the Ethical
Committee of Leeds (East) Research Ethics Committee
(REC reference number 05/Q1206/80) and informed
consent was collected from the subject and parents. The
skin biopsy was finely cut and homogenised to desegre-
gate the cells prior to plating in Hams F10 medium con-
taining L-glutamine and 25 mM HEPES (Invitrogen,
Paisley, U.K.), 20% fetal calf serum (Invitrogen) and 1%
penicillin/streptomycin (Invitrogen) and incubated in 5%
CO2 at 37°C
Antibodies and Cytotoxic reagents
Rabbit polyclonal antibodies against peptide sequences
corresponding to aa363-386 (sequence code 216-1;
KDNYGLNQDLESES), aa426-441 (sequence code 217-2;
PEDWRKSEVSPRIPEC) and aa3443-3458 (sequence
code 279-3; SRLKPDWVLRRDNMEE) of the human
ASPM sequence were raised by Affiniti Research Pro-
ducts Limited, Exeter, UK. BLAST analysis revealed no
significant homology to other published sequences.
Antibody specificity in immunostaining was demon-
strated by peptide pre-competition of immune serum
and lack of specific staining from pre-immune serum
(not shown). A rat anti a-tubulin antibody was obtained
from Serotec Ltd, Oxford, UK. A mouse monoclonal
antibody specific for g-tubulin was obtained from the
Sigma-Aldrich Company, Dorset, UK. Mouse monoclo-
nal and rabbit polyclonal anti-GFP antibodies were
obtained from Clontech (Saint-Germain-en-Laye,
France). Secondary antibodies were Molecular Probes
highly cross-absorbed rabbit, mouse or rat IgG-specific
Alexa conjugates (Cambridge BioScience, Cambridge,
UK). DAPI, nocodazole and taxol were obtained from
the Sigma-Aldrich Company.
Immunofluorescence
Cells were cultured on glass coverslips. Transfections of
GFP-constructs were performed using GeneJuice (Nova-
gen) according to the manufacturer’s instructions and
coverslips were processed for immunocytochemistry 24
hours after transfection. Cells were fixed for 5 minutes
in ice-cold methanol and labelled as previously
described [48]. Immunofluorescence analysis was per-
formed using a Leica TCS-SP confocal microscope as
described previously [49] and a Zeiss Axiovert 200
inverted microscope coupled to an Orca II ER CCD
camera controlled by AQM6 software (Kinetic Imaging,
Wirral, UK) as described previously [50]. All confocal
images presented here are maximum intensity projec-
tions. Figures were assembled and annotated using
Adobe Photoshop CS2.
Immunoblotting
To perform immunoblotting of ASPM, cells were lysed
in standard RIPA buffer, protein concentration deter-
mined and PAGE carried out using 3-8% Tris Acetate
precast gradient gels (Invitrogen) in a Surelock electro-
phoresis tank (Invitrogen) on 25 μg protein. Subsequent
protein transfer onto PVDF membrane (Invitrogen) was
performed in the same system in accordance with the
manufacturer’s instructions.
siRNA knockdown of ASPM expression
Double-stranded RNA oligos that target ASPM mRNA
were obtained from Dharmacon Inc Lafayette, CO,
USA. siRNA ASPM1 targets sequence UGCCAUGGUG-
CAACUUGCU (nt 691-709) (synthetic oligos UGCCAU
GGUGCAACUUGCUUU and AGCAAGUUGCACC
AUGGCAUU) and siRNA ASPM2 targets GUGGUG
AAGGUGACCUUUC (nt 2804-2822) (synthetic oligos
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CCUUCACCACUU). A GL3 siRNA targeting the firefly
luciferase sequence CUUACGCUGAGUACUUCGA was
used as a control [51].
5×1 0
5 U2OS cells per well of a six well plate con-
taining a coverslip or 4 × 10
5 U2OS cells per 35 mm
plate for live cell imaging experiments were transfected
16 hours post plating with siRNA using Oligofectamine
transfection reagent (Invitrogen). siRNA transfection
mix was prepared for each plate as follows; 12 μlo f2 0
μMs i R N Aw a sa d d e dt o2 0 0μlO p t i m e ms e r u mf r e e
medium (Invitrogen). 8 μl of Oligofectamine was added
to 52 μl Optimem medium in a separate tube and incu-
bated at room temperature for 10 minutes. The diluted
transfection reagent was added to the tube containing
the diluted siRNA and incubated for a further 20 min-
utes. 128 μl of Optimem was then added to give a final
siRNA transfection mix volume of 0.4 ml. The growth
medium was removed from the cells which were washed
once with growth medium without serum or antibiotics.
0.6 ml growth medium without serum or antibiotics was
added to the plate, followed by the 0.4 ml transfection
mix. The transfection was incubated at 37°C for 4 hours
before adding 1 ml growth medium containing 20% FCS
and antibiotics. The cells were incubated for a total of
48 or 72 hours before analysis.
FACS analysis of DNA content
48 and 72 hours after siRNA treatment U2OS cells were
released by trypsin digestion, pelleted, washed in PBS
and resuspended in 1 ml of cold 70% ethanol then
stored at -20°C. Prior to Flow Cytometric analysis the
cells were washed in block buffer (PBS containing 1%
BSA), permeabilised for 15 minutes in block buffer con-
taining 0.25% Triton X-100 and then incubated for 1
hour in 100 μl of mouse anti cyclin B1 (BD-Pharmingen
554177 diluted 1:500). Cells were washed in block buffer
then incubated for 1 hour with Alexa Fluor 488 anti-
mouse IgG (Molecular probes A-11029, diluted 1:300).
Cells were finally washed and then incubated at 37°C
for 30 min in 0.5 ml PBS containing 3 μlo f6m g / m l
RNAse and 12.5 μl of 5 mg/ml propidium iodide. 10,000
single cell events per sample were analysed for DNA
and cyclin B1 content to identify G1 (2N DNA content,
low cyclin B1), G2/M (4N DNA content, high cyclin B1)
and tetraploid cells (4N DNA content, low cyclin B1)
using a Facscalibur Facscan (Becton Dickinson).
CaspGLOW™ Fluorescein Active Caspase-3 Assay
U2OS cells were treated with GL3 or ASP1 siRNA
d u p l e xf o r9 6h o u r sp r i o rt oc o m m e n c i n gC a s p a s e - 3
analysis. Detached and adherent cells were collected and
washed with PBS. The CaspGLOW™ Fluorescein Active
Caspase-3 assay (Medical and Biological Laboratories
Ltd, Woburn, MA, USA) was performed on 3 × 10
5
GL3 and ASP1 treated cells as per manufacturer’s proto-
col. The cells were then resuspended in PBS containing
50 ug/ml propidium iodide, 100 ug/ml RNAse A and
0.1% (v/v) Triton X-100 and incubated at 37°C for one
hour. Active caspase-3 was detected by flow cytometry
using a BD LSRII (Becton Dickinson) capturing 10000
events per sample. Three independent experiments were
performed
Time-lapse live cell imaging
Phase contrast time-lapse imaging experiments of live
cells were performed on a Zeiss Axiovert 200 M
inverted microscope incorporating an automated
motorised stage, contained within a Perspex incubation
chamber heated to a constant 37°C temperature (Solent
Scientific, UK). Cells were cultured, transfected and
imaged in 35 mm glass-bottomed culture dishes (Iwaki
brand; Asahi Techno Glass Corporation, Japan, obtained
from Barloworld Scientific, UK). Growth media was
replaced with 2 ml media supplemented with 20 mM
HEPES. Cells were observed under oil with an ×40 Plan
Neofluar 1.3 aperture objective. Images were captured
with a Hamamatsu Orca Camera, using Volocity 3
acquisition software (Improvision, Coventry, UK) over a
period of 4 hours. Multiple positions were imaged at a
rate of one image per minute. Live cell fluorescence
imaging experiments were performed on a Zeiss Axio-
vert 200 inverted microscope contained within a Perspex
incubation chamber heated to a constant 37°C tempera-
ture (Solent Scientific, UK). Imaging was performed as
described previously [50]. Figures were assembled and
annotated using Adobe Photoshop CS2.
Celltitre Blue cell viability assay and assessment of
mitotic abnormalities in fixed immunolabelled siRNA
treated cells
To perform cell viability assays on siRNA treated cells,
U2OS cells were plated in 96-well plates at 10
3 cells per
well and grown at 37°C for 16 hours before siRNA treat-
ment (as above). Wells were washed once with serum
free medium and then 60 μl serum free medium and 40
μl siRNA transfection mix were added. The transfection
was completed as described above. 72 hours after siRNA
transfection, Celltitre Blue reagent (Promega) was added
to wells following manufacturer’s instructions. The plate
was incubated at 37°C for a further 8 hours and the
conversion of resazurin to fluorescent resorufin, an
assay of metabolic rate, was determined using fluorime-
try (560 nm excitation wavelength, 615 nm emission
wavelength). In parallel experiments siRNA treated and
control cell cultures were co-immunostained using com-
binations of antibodies that included a-tubulin, g-tubu-
lin and ASPM. DNA was counterstained using DAPI. At
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direct microscopic observation to determine mitotic
index, the number of cells in cytokinesis, and the pro-
portion of cells with abnormal numbers of nuclei and
centrosomes.
T cell lines and GL3, ASP1 and ASP2 treated U2OS
cells",1,0,1,0,0pc,0pc,0pc,0pc>Comparative analysis of
ASPM spindle pole expression in ASPM
wt, ASPM
IVS25 +1G >
T cell lines and GL3, ASP1 and ASP2 treated U2OS cells
To compare relative quantities of ASPM at the spindle
poles of ASPM
wt and ASPM
IVS25 +1G > T cells, cells were
simultaneously immunofluorescently labelled using 216-1
anti-ASPM antibody. Images were captured on an Olym-
pus BX61 upright microscope using ×100 oil UPlanFLN
1.30 aperture objective, F-View II monochromatic cam-
era (Olympus Soft Imaging Solutions Ltd, Helperby,
North Yorkshire, U.K.) and Cell
P Software (Olympus Soft
Imaging Solutions Ltd), with a 1 second exposure time,
ensuring the signal intensities visualised in the images
were directly comparable. ASPM PCM signal intensity
was measured as integral intensity (defined as the sum of
all the intensities of a region of interest multiplied by the
pixel area). To compare the integral integrity values of
ASPM localised at the spindle pole in ASPM
wt and
ASPM
IVS25 +1G > T cells a paired two tailed Student t-test
was used. A P-value of less than 0.0001 was considered
highly statistically significant.
To compare the integral integrity values of ASPM loca-
lised at the spindle pole in GL3, ASP1 and ASP2 treated
metaphase U2OS cells captured with a 2 second exposure
time, a Mann Whitney test was used. A P-value of less
than 0.005 was considered statistically significant.
RNA preparation, reverse transcription and sequencing
RNA was obtained from ASPM
wt and ASPM
IVS25 +1G > T
fibroblasts using Trizol extraction as per manufacturers
instructions. cDNA was produced using Superscript
reverse transcriptase (Stratagene Agilent Technologies,
West Lothian, UK) as per manufacturers direction with
oligo dT primers (Promega). ASPM exons 25-28 were
amplified using forward (TCCGAAGTTGTAATCGC
AGT) and reverse (CTTGCAGGGGATTTGTGATT)
primers.
Plasmid construction
The plasmids pASPM-D1-GFP, pASPM-D2-GFP and
pASPM-D3-GFP were constructed by cloning nt 9530-
10434 (aa3177-3477), 9766-10434 (aa3256-3477) and
9943-10434 (aa3315-3477) of ASPM respectively in frame
into the BamHI and XhoI restriction sites in the GFP
expression plasmid pJMA2-eGFP [49]. All constructs
were fully sequenced before use. The construction and
characterization of an EB3-GFP expression plasmid will
be described elsewhere (J. M. Askham, manuscript in
preparation).
Additional material
Additional file 1: A comparison of ASPM interphase localisation in
HDF cells using ASPM N-a n dC-terminal ASPM antibodies. Cells
were fixed and stained with the N-terminal ASPM antibody 216-1 or 217-
2o rt h eC-terminal antibody 279-3 (green), anti-a-tubulin (red) and DAPI
(blue) to identify nuclei. Scale bar = 10 μm.
Additional file 2: A comparison of ASPM metaphase localisation in
HDF cells using ASPM N-a n dC-terminal ASPM antibodies. Cells
were fixed and stained with the N-terminal ASPM antibody 216-1 or 217-
2o rt h eC-terminal antibody 279-3 (green), anti-a-tubulin (red) and DAPI
(blue) to identify nuclei. Scale bar = 10 μm.
Additional file 3: ASPM is localised at the spindle poles in
metaphase cells for a range of cell types. HeLa, COS-7, U2OS, SH-SY5Y
and HDF cells were fixed and stained with the N-terminal ASPM
antibody 216-1 (green), anti-a-tubulin (red) and DAPI (blue) to identify
nuclei. Scale bar = 10 μm.
Additional file 4: ASPM is positioned in a narrow ring at the centre
of the midbody during telophase in a range of cell types. Cells were
fixed and stained with the N-terminal ASPM antibody 279-3 (green), anti-
a-tubulin (red) and DAPI (blue) to identify nuclei. Scale bar = 10 μm.
Additional file 5: Symmetrical division in GL3 luciferase control
siRNA treated cells. A U2OS cell treated with GL3 siRNA undergoing
symmetrical division with the mitotic spindle parallel to the surface of
the imaging dish. This division results in two daughter cells and
complete cytokinesis.
Additional file 6: Asymmetrical division and cytokinesis failure in a
siRNA mediated ASPM depleted U2OS cell. A U2OS cell treated with
ASP1 siRNA undergoing an asymmetric division with the mitotic spindle
perpendicular to the surface of the imaging dish. This results in one
daughter being extruded vertically from the dividing cell, towards the
observer, while the other remains attached to the substrate. In this
example cytokinesis fails, resulting in the formation of a binucleate cell.
Additional file 7: ASPM depleted binucleate U2OS cell undergoing
apoptosis. This movie shows a binucleate U2OS cell following treatment
with ASP1 siRNA, undergoing apoptosis.
Abbreviations
ASPM: Abnormal spindle-like microcephaly associated; CDK5RAP2: CDK5
regulatory subunit-associated protein 2; CENPJ: Centromeric protein J;
DCNT1: Dynactin1; FACS: Fluorescence-activated cell sorter; GFP: Green
fluorescent protein MCPH: Autosomal recessive primary microcephaly; NPC:
Neural progenitor cell; NMD: Nonsense mediated decay; nt: Nucleotide; PBS:
Phosphate buffered saline; s.d.: Standard deviation; s.e.m.: Standard error of
the mean; siRNA: Small interfering RNA
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